Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Comment
. 2020 Jun 15;201(12):1578-1579.
doi: 10.1164/rccm.202001-0201LE.

High-Dose First-Line Treatment Regimen for Recurrent Rifampicin-Susceptible Tuberculosis

Tom Decroo  1   2 , Bouke C de Jong  1 , Alberto Piubello  3   4 , Mahamadou Bassirou Souleymane  3 , Lutgarde Lynen  1 , Armand Van Deun  5
Affiliations
Comment

High-Dose First-Line Treatment Regimen for Recurrent Rifampicin-Susceptible Tuberculosis

Tom Decroo et al. Am J Respir Crit Care Med. .
No abstract available

PubMed Disclaimer

Comment in

Comment on

References

    1. Dooley KE, Miyahara S, von Groote-Bidlingmaier F, Sun X, Hafner R, Rosenkranz SL, et al. A5312 Study Team. Early bactericidal activity of different isoniazid doses for drug resistant TB (INHindsight): a randomized open-label clinical trial. Am J Respir Crit Care Med. [online ahead of print] 16 Jan 2020; DOI: 10.1164/rccm.201910-1960OC. - PMC - PubMed
    1. World Health Organization WHO treatment guidelines for isoniazid-resistant tuberculosis: supplement to the WHO treatment guidelines for drug-resistant tuberculosis WHO/CDS/TB/2018 2018[accessed 2020 Jan 29]. Available from: https://www.who.int/tb/publications/2018/WHO_guidelines_isoniazid_resist.... - PubMed
    1. Van Deun A, Aung KJM, Bola V, Lebeke R, Hossain MA, de Rijk WB, et al. Rifampin drug resistance tests for tuberculosis: challenging the gold standard. J Clin Microbiol. 2013;51:2633–2640. - PMC - PubMed
    1. Katiyar SK, Bihari S, Prakash S, Mamtani M, Kulkarni H. A randomised controlled trial of high-dose isoniazid adjuvant therapy for multidrug-resistant tuberculosis [letter] Int J Tuberc Lung Dis. 2008;12:139–145. - PubMed
    1. Boeree MJ, Heinrich N, Aarnoutse R, Diacon AH, Dawson R, Rehal S, et al. PanACEA consortium. High-dose rifampicin, moxifloxacin, and SQ109 for treating tuberculosis: a multi-arm, multi-stage randomised controlled trial. Lancet Infect Dis. 2017;17:39–49. - PMC - PubMed